http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006028961-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4d0b1be5fd2a9430a16128d51a7cdb0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a069a5f16af3098d897b0321308063f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2ededd0c0d618214c3c5c7515976c6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50ccb96dfc2edbdef32d4b806303199a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407
filingDate 2005-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b1f01a5f8ebf6b1cf5fa7e8cd36d9a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_994320bdb1303225232a29814dafd413
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6703426ce696748510307f0a5455e1b6
publicationDate 2006-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2006028961-A3
titleOfInvention Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators
abstract The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
priorityDate 2004-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4414225-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5202
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228069437
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394200
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411291859
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226770344
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID67205591
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66689195
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419549034

Total number of triples: 38.